A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for Advanced Stomach
Satoshi Morita1, Hideo Baba, Akira Tsuburaya
1Department of Medical Administration, Program in Health and Community Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan. smorita@med.nagoya-u.ac.jp
Abstract:
A randomized phase II clinical trial is being conducted for patients with advanced or recurrent gastric cancer, in order to select the most promising treatment for subsequent evaluation in a large-scale phase III trial. We compare four chemotherapeutic treatments, which include two sequential and two combination regimens using paclitaxel with 5-fluorouracil or S-1, an oral fluorouracil derivative. The primary endpoint is 10-month overall survival rate, while the secondary endpoints are adverse events, time to treatment failure and progression-free survival. A Bayesian method is used to provide a statistical rule for monitoring the trial. Forty patients per treatment regimen (160 in total) were randomized into one of the four regimens using a centralized dynamic method.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers

